Torrent Pharma Dahej plant clears USFDA with zero, 2026

Overview: Dahej facility gets a clean USFDA outcome

Torrent Pharmaceuticals Limited said its manufacturing facility at Dahej, Gujarat, has cleared a US Food and Drug Administration (USFDA) inspection with zero observations. The company disclosed the outcome to stock exchanges under Regulation 30 of the SEBI Listing Regulations. The inspection was conducted over five days and ended without any adverse findings, the company said. For investors, the development is closely watched because regulatory outcomes influence the pace of approvals and continuity of supplies into the US market.

Inspection details: dates and the key regulatory outcome

Torrent Pharma said the USFDA inspected the Dahej unit from January 19, 2026, to January 23, 2026. The company stated the inspection concluded with no Form 483 being issued. In USFDA terminology, a Form 483 lists inspectional observations that the regulator expects a company to address. A “no Form 483” closeout is generally read as a clean inspection outcome for the period under review, based on the company’s disclosure.

Why “no Form 483” matters for US-facing pharma plants

For Indian drugmakers, USFDA inspections are a critical operating gate for manufacturing sites that supply the US, a key export market. Observations can lead to remediation commitments and can also slow down product approval work linked to a site, depending on the severity and follow-up. Against that backdrop, Torrent’s statement that the Dahej audit ended with zero observations signals regulatory comfort with the facility’s systems during the inspection window. The company did not add further operational details in the disclosure shared in the provided text.

Market reaction: shares slip despite the Dahej update

In the trading commentary included in the provided material, Torrent Pharma’s stock was also discussed in the context of observations at another facility. Shares of Torrent Pharmaceuticals fell as much as 3.26% to an intraday low of Rs 2,800.05 per share on Thursday, according to the report. At 10:53 AM, the stock was trading 0.92% lower at Rs 2,867.80 per share. Over the same time, the BSE Sensex was 0.28% higher at 76,820.20.

Indrad unit (June 2024): Form 483 with five observations

The same set of materials also references an earlier USFDA action at Torrent’s Indrad facility in Gujarat. Torrent Pharma said the USFDA conducted a Pre-Approval Inspection (PAI) and a good manufacturing practice (GMP) inspection at Indrad from June 3, 2024, to June 12, 2024. At the end of that inspection, the company said it received a Form 483 with five observations. Torrent also stated that “there was no observation related to data integrity reported.” The company said it would respond within the prescribed time-frame and work in close collaboration with the agency to address the observations at the earliest.

Indrad unit (September 2022): three observations and OAI classification

The material further notes that Torrent said the USFDA inspected its Indrad facility from September 19, 2022, to September 28, 2022, and issued a Form 483 with three observations. Following that, Torrent said it received an inspection classification of “Official Action Indicated” (OAI) for the Indrad facility. Torrent stated that this inspection classification would not have an impact on existing supplies or revenues from the facility. It also said the Indrad site makes formulations and active pharmaceutical ingredients (APIs) and has an annual capacity of 30 million vials, as per the company’s website. In that report, Torrent Pharmaceuticals shares were cited at ₹1,589.90, down 0.5% from the previous close on the NSE.

Indrad unit (2019): warning letter and CGMP concerns

The provided text also includes excerpts from an October 8, 2019 warning letter related to the Indrad facility, referencing an inspection conducted from April 8 to April 16, 2019. The letter described significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, referencing 21 CFR parts 210 and 211. It also stated the agency may withhold approval of new applications or supplements listing the site until compliance is confirmed, and could refuse admission of products manufactured at the facility into the United States if violations are not corrected. Separately, a market report cited Torrent’s disclosure that the warning letter followed an earlier intimation in August 2019 where the inspection was classified as OAI.

What the company has said across filings

Across the Indrad-related disclosures quoted in the provided material, Torrent’s messaging is consistent on process: it plans to respond within the prescribed timelines and work with the USFDA to address observations. For the June 2024 inspection, it specifically said no data integrity observation was reported. For the January 2026 Dahej inspection, the key disclosure was that the audit concluded with zero observations and no Form 483. The company did not provide additional specifics on products, batches, or pending approvals in the text provided.

Key facts at a glance

Conclusion

Torrent Pharma’s disclosure that its Dahej facility closed a USFDA inspection in January 2026 with zero observations is a clear compliance positive for that site. At the same time, the broader set of reports in the provided material shows investors also track outcomes at Indrad, including a June 2024 Form 483 with five observations and earlier enforcement history. The next confirmed steps, based on the disclosures quoted, are Torrent’s formal responses to USFDA observations for Indrad within the regulator’s prescribed timelines and continued engagement with the agency.